Allogene Therapeutics Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | 121.7 | 91.7 | 91.6 | 53.9 | 6,274.8 | 6,617.8 | 6,281.6 | 3,737.2 | 3,341.3 | 4,959.3 | 4,433.7 | 17,955.8 | 34,594.4 | – | – | – | – | – | – | – | – | 148.9 | |
| – | – | – | – | 3.1 | 4.1 | 4.1 | 4.5 | 4.3 | 3.5 | 4.2 | 4.3 | 3.0 | 4.4 | 3.4 | 3.6 | 2.2 | 1.5 | 2.0 | 2.1 | 1.4 | 1.2 | 1.2 | 0.9 | 1.1 | 1.6 | 0.8 | 1.3 | 1.0 | 0.8 | 0.7 | 0.8 | 1.1 | 2.1 | 1.6 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 116.8 | – | – | 49.5 | – | 6,250.6 | 6,004.1 | 3,507.1 | 2,852.0 | 3,956.8 | 3,915.8 | 15,409.8 | 32,589.4 | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -2.2% | -3.1% | -4.3% | -5.3% | -6.9% | -9.5% | -4.3% | -4.5% | -5.5% | -3.9% | -5.5% | -5.3% | -9.9% | -17.2% | -13.0% | -13.4% | -24.9% | -31.5% | -32.9% | -46.4% | -44.4% | -29.9% | -52.4% | -37.2% | -45.5% | -61.3% | -72.1% | -59.7% | -48.4% | -19.0% | -14.9% | |
| Margins | |||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | -293.6% | -170.0% | -35.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -2,852.1% | -11,806.7% | -32,295.5% | – | – | – | – | – | – | – | – | -699.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -609.6% | -629.4% | -653.7% | -664.6% | -147,602.0% | -124,756.7% | -126,707.7% | -138,044.9% | -167,240.1% | -242,226.4% | -280,166.9% | -1,092,673.3% | -1,355,518.2% | – | – | – | – | – | – | – | – | -3,886.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -596.6% | -621.8% | -652.2% | -667.7% | -148,214.6% | -124,571.3% | -126,580.2% | -136,885.6% | -166,391.5% | -241,348.0% | -277,962.0% | -1,102,480.0% | -1,344,436.4% | – | – | – | – | – | – | – | – | -3,566.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -479.3% | -502.9% | -487.7% | -535.9% | -107,613.7% | -86,008.5% | -84,248.6% | -92,884.8% | -105,304.2% | -163,165.5% | -205,908.3% | -797,496.7% | -1,034,009.1% | – | – | – | – | – | – | – | – | -2,211.2% | |
| Returns | |||||||||||||||||||||||||||||||||||
| – | – | – | – | -30.1% | -35.3% | -22.4% | -24.9% | -29.3% | -34.2% | -19.5% | -21.7% | -23.2% | -21.4% | -23.3% | -25.8% | -27.8% | -35.5% | -38.4% | -42.3% | -49.9% | -59.6% | -57.3% | -57.7% | -64.6% | -64.1% | -54.9% | -61.9% | -61.0% | -65.5% | -68.8% | -67.2% | -65.3% | -62.3% | -37.9% | |
| – | – | – | -41.6% | -27.3% | -32.1% | -20.0% | -22.2% | -25.7% | -30.1% | -18.1% | -19.9% | -20.4% | -19.4% | -21.2% | -23.2% | -24.5% | -31.5% | -32.5% | -35.2% | -40.5% | -47.2% | -46.3% | -47.2% | -51.5% | -50.4% | -43.7% | -48.7% | -46.9% | -49.7% | -50.3% | -48.2% | -45.9% | -43.9% | -30.1% | |
| Balance Sheet & Debt | |||||||||||||||||||||||||||||||||||
| – | – | – | 82 | -687 | -58 | – | – | -173 | – | – | -107 | -180 | -185 | – | – | -170 | – | -91 | -69 | -56 | -104 | -148 | -63 | -76 | -44 | -163 | -44 | -68 | -35 | -45 | -30 | -43 | -22 | – | |
| – | 0.0% | 94.2% | -38.7% | 90.9% | 90.9% | 89.3% | 89.1% | 87.6% | 88.1% | 92.4% | 91.5% | 87.9% | 90.7% | 90.9% | 89.9% | 88.0% | 88.7% | 84.6% | 83.4% | 81.2% | 79.3% | 80.8% | 81.9% | 79.7% | 78.7% | 79.6% | 78.7% | 76.9% | 75.9% | 73.2% | 71.7% | 70.3% | 70.4% | 79.3% | |
| – | – | – | – | 0.0 | 0.1 | – | – | 0.0 | – | – | 0.0 | 0.0 | 0.0 | – | – | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| Per Share | |||||||||||||||||||||||||||||||||||
| – | – | – | -1.59 | -2.58 | -2.47 | -1.47 | -1.51 | -1.76 | -1.90 | -1.97 | -1.91 | -1.93 | -1.73 | -1.77 | -1.83 | -1.85 | -2.15 | -2.15 | -2.18 | -2.31 | -2.44 | -2.43 | -2.01 | -1.96 | -1.75 | -1.49 | -1.37 | -1.22 | -1.17 | -1.08 | -0.95 | -0.87 | -0.72 | -0.50 | |
| – | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.28 | 0.28 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| 0.00 | 0.00 | 2.48 | -1.48 | 8.57 | 7.00 | 6.57 | 6.06 | 6.00 | 5.57 | 10.08 | 8.80 | 8.32 | 8.09 | 7.59 | 7.08 | 6.65 | 6.05 | 5.59 | 5.15 | 4.63 | 4.10 | 4.24 | 3.48 | 3.04 | 2.73 | 2.71 | 2.22 | 2.00 | 1.79 | 1.57 | 1.42 | 1.33 | 1.16 | 1.33 | |
| – | – | – | – | -0.58 | -0.91 | -1.15 | -1.43 | -1.80 | -1.84 | -1.82 | -1.72 | -1.39 | -1.39 | -1.43 | -1.37 | -1.48 | -1.56 | -1.48 | -1.45 | -1.57 | -1.54 | -1.65 | -1.49 | -1.42 | -1.35 | -1.20 | -1.04 | -0.95 | -0.92 | -0.79 | -0.72 | -0.68 | -0.46 | -0.31 | |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.